Catalyst Pharmaceuticals Stock Investor Sentiment

CPRX Stock  USD 22.78  0.12  0.53%   
Slightly above 53% of Catalyst Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that some traders are interested. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  

Catalyst Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Catalyst Pharmaceuticals Maximum Pain Price Across March 21st 2025 Option Contracts

Catalyst Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Catalyst Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Catalyst Pharmaceuticals' options.
few days ago at news.google.com         
Catalyst Pharma Highlights Growth in Rare Diseases Sector - TipRanks
Google News at Macroaxis
six days ago at thelincolnianonline.com         
Catalyst Pharmaceuticals Trading 13 percent Higher Heres What Happened
news
six days ago at thelincolnianonline.com         
Catalyst Pharmaceuticals Price Target Raised to 35.00 at HC Wainwright
news
over a week ago at benzinga.com         
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
benzinga news
over a week ago at zacks.com         
CPRX Stock Rises 17 percent on Settling Firdapse Patent Litigation With Teva
zacks News
over a week ago at zacks.com         
Heres Why Momentum in Catalyst Should Keep going
zacks News
over a week ago at gurufocus.com         
Disposition of 50000 shares by Denkhaus Donald A of Catalyst Pharmaceuticals at 2.24 subject to Rule...
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE amif
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Catalyst Pharmaceuticals Inc Announces Settlement with Teva Pharmaceuticals
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceutical...
Yahoo News
over a week ago at globenewswire.com         
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceutical...
Macroaxis News: globenewswire.com
over a week ago at simplywall.st         
Catalyst Pharmaceuticals earnings growth rate lags the 37 percent CAGR delivered to shareholders
Simply Wall St News at Macroaxis
over a week ago at zacks.com         
Heres Why Catalyst Pharmaceutical is a Strong Growth Stock
zacks News
over two weeks ago at www.macroaxis.com         
Disposition of 10600 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 8667 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.

Catalyst Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 3410 shares by Grande Alicia of Catalyst Pharmaceuticals subject to Rule 16b-3
10/25/2024
2
Pick These 4 Solid Net Profit Margin Stocks to Boost Portfolio Return
10/28/2024
3
Disposition of 230000 shares by Patrick McEnany of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3
11/11/2024
4
Disposition of 192000 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject to Rule 16b-3
11/12/2024
5
Disposition of 72500 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject to Rule 16b-3
11/20/2024
6
Acquisition by Thompson Tamar of 23248 shares of Catalyst Pharmaceuticals at 21.12 subject to Rule 16b-3
11/21/2024
7
Disposition of 9300 shares by Elsbernd Brian of Catalyst Pharmaceuticals at 21.65 subject to Rule 16b-3
11/26/2024
8
Disposition of 17500 shares by Harper Molly of Catalyst Pharmaceuticals at 22.0 subject to Rule 16b-3
11/27/2024
9
Disposition of 2355 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3
12/09/2024
10
Hohimer Wealth Management LLC Buys Shares of 16,543 Catalyst Pharmaceuticals, Inc.
12/11/2024
11
Acquisition by Miller Steve of 235000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3
12/13/2024
12
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16/2024
13
Wellington Management Group LLP Makes New 1.19 Million Investment in Catalyst Pharmaceuticals, Inc. - MarketBeat
12/20/2024
14
Acquisition by Harper Molly of 1333 shares of Catalyst Pharmaceuticals subject to Rule 16b-3
12/27/2024
15
Disposition of 8667 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3
12/31/2024
16
Disposition of 10600 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3
01/02/2025
17
Catalyst Pharmaceuticals earnings growth rate lags the 37 percent CAGR delivered to shareholders
01/07/2025
18
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceuticals
01/08/2025
19
Catalyst Pharma Highlights Growth in Rare Diseases Sector - TipRanks
01/13/2025

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.